Published in:
Open Access
01-04-2018 | Validation Studies
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
Authors:
Erkan Demirkaya, Seza Ozen, Betul Sozeri, Nuray Aktay Ayaz, Ozgur Kasapcopur, Erbil Unsal, Balahan Bora Makay, Kenan Barut, Berna Eren Fidanci, Dogan Simsek, Mustafa Cakan, Alessandro Consolaro, Francesca Bovis, Nicolino Ruperto, For the Paediatric Rheumatology International Trials Organisation (PRINTO)
Published in:
Rheumatology International
|
Special Issue 1/2018
Login to get access
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 466 JIA patients (13.7% systemic, 40.6% oligoarticular, 22.5% RF negative poly-arthritis, and 23.2% other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.